ABCA1 Upregulation via LXRβ Agonism to Enhance Cholesterol Efflux and Prevent Neuroinflammatory Lipid Accumulation

This hypothesis proposes that selective LXRβ agonism primarily functions through transcriptional upregulation of ABCA1 (ATP-binding cassette transporter A1) to facilitate cholesterol efflux from activated microglia and prevent pathological lipid accumulation in neuroinflammatory conditions. LXRβ activation would induce ABCA1 expression, creating a robust cholesterol export mechanism that reduces intracellular cholesterol burden in microglia while simultaneously promoting the formation of properly lipidated APOE particles. The mechanism centers on ABCA1's role as the rate-limiting step in cholesterol efflux, where increased ABCA1 expression creates a metabolic sink that drives cholesterol mobilization from microglial lipid droplets and membrane domains.

This hypothesis proposes that selective LXRβ agonism primarily functions through transcriptional upregulation of ABCA1 (ATP-binding cassette transporter A1) to facilitate cholesterol efflux from activated microglia and prevent pathological lipid accumulation in neuroinflammatory conditions. LXRβ activation would induce ABCA1 expression, creating a robust cholesterol export mechanism that reduces intracellular cholesterol burden in microglia while simultaneously promoting the formation of properly lipidated APOE particles. The mechanism centers on ABCA1's role as the rate-limiting step in cholesterol efflux, where increased ABCA1 expression creates a metabolic sink that drives cholesterol mobilization from microglial lipid droplets and membrane domains. This enhanced efflux capacity would prevent the formation of foam cell-like microglia that are characteristic of neuroinflammation and neurodegeneration. Concurrently, the exported cholesterol would be captured by lipid-poor APOE particles, converting them to lipidated, functional forms that can effectively clear amyloid deposits and support neuronal membrane repair. The hypothesis predicts that LXRβ-selective agonists would demonstrate superior efficacy compared to pan-LXR agonists by avoiding hepatic lipogenesis while maximizing brain-specific ABCA1 upregulation. Experimental validation would involve measuring ABCA1 protein levels, cholesterol efflux rates from primary microglia, and the lipidation status of APOE particles in cerebrospinal fluid following LXRβ agonist treatment. This approach targets the mechanistic bottleneck of cholesterol export rather than broad metabolic reprogramming.